Neuraxis, INC (New York Stock Exchange Arca:NRXS)
| Market Cap | $59.90M+63.6% |
| Revenue (ttm) | $6.53M+94.3% |
| Net Income | -$12.29M-63.0% |
| EPS | -$1.05-1.9% |
| Shares Out | 14.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151,407 |
| Open | $4.40 |
| Previous Close | $4.50 |
| Day's Range | $4.22 - $4.45 |
| 52-Week Range | $2.50 - $9.33 |
| Beta | 1.38 |
| Analysts | Buy |
| Price Target | $8.00(+89.57%) |
| Earnings Date | Mar 18, 2027 |
About NRXS
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Neuraxis, INC Stock Analysis — InsiderScore
Neuraxis, INC scored higher than 11% of companies evaluated by InsiderBuying, and ranked 76th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Neuraxis, INC bought $12.3K of stock across 3 purchases in the last 90 days, the largest of them $9.4K.
The average purchase added about 9% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 18, 2027Earnings report
$NRXS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NRXS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NRXS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NRXS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NRXS Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NRXS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NRXS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NRXS
| VTIVanguard Morningstar Total Stock Market ETF | $1.25M |
| VXFVanguard Extended Market ETF | $781.14K |
| IWCiShares Micro-Cap ETF | $122.89K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $70.00K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from NRXS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Record quarterly revenue with 150% YoY growth represents substantial business outperformance and positive earnings catalysts.
Recent Insider Activity
Insider Score Trend Over Time
-13.0 since Oct 9Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.08% |
Weight is the stock’s share of each fund’s holdings.
